| Investigator . | Institution (specialty) . | Conflict of interest disclosure statement . |
|---|---|---|
| Michael S. Gordon, MD (ASCO Co-Chair, TEC panel member) | Univ of Arizona HSC Phoenix, AZ (medical oncology/hematology) | Consultant within the last 2 years for Amgen; received research funding from Amgen; received honoraria directly in excess of $2000 per year or $5000 over a 3-year period from Amgen; a member on the Board of Directors or Advisory Committee of Amgen. |
| Alan E. Lichtin, MD (ASH Co-Chair, TEC panel member) | Cleveland Clinic Foundation Cleveland, OH (medical oncology/hematology) | No conflicts noted. |
| Charles L. Bennett, MD, PhD (TEC panel member) | VA Chicago Health Care System Chicago, IL (medical oncology/hematology) | Consultant within the last 2 years for OrthoBiotech and Amgen; received research funding from OrthoBiotech and Amgen. |
| David Cella, PhD | Evanston Northwestern Healthcare Evanston, IL (quality of life) | Consultant within the last 2 years for Amgen and OrthoBiotech; received research funding from Amgen and OrthoBiotech; received honoraria directly in excess of $2000 per year or $5000 over a 3-year period from Amgen and OrthoBiotech. |
| Benjamin Djulbegovic, MD, PhD | H. Lee Moffitt Cancer Ctr, Univ of South Florida Tampa, FL (medical oncology/hematology) | No conflicts noted. |
| Matthew J. Goode | Mesa, AZ (patient representative) | No conflicts noted. |
| Ann A. Jakubowski, MD, PhD | Memorial Sloan-Kettering Cancer Ctr New York, NY (medical oncology/hematology) | No conflicts noted. |
| Stephanie J. Lee, MD, MPH | Dana Farber Cancer Inst Boston, MA (medical oncology/hematology) | No conflicts noted. |
| Carole B. Miller, MD | St Agnes Hospital Baltimore, MD (medical oncology) | Received research funding from OrthoBiotech and Amgen; received honoraria directly in excess of $2000 per year or $5000 over a 3-year period from Amgen. |
| Mark U. Rarick, MD | NW Kaiser Permanente Portland, OR (hematology) | No conflicts noted. |
| David H. Regan, MD | Northwest Cancer Specialists Portland, OR (hematology) | No conflicts noted. |
| Steven H. Woolf, MD, MPH | Virginia Commonwealth Univ Fairfax, VA (internal medicine/methodological consultant) | No conflicts noted. |
| J. Douglas Rizzo,* MD | Medical College of Wisconsin IBMTR/ABMTR Milwaukee, WI (medical oncology/hematology) | No conflicts noted. |
| George P. Browman,* MD | Hamilton Regional Cancer Ctr Hamilton, Ontario Canada (medical oncology) | No conflicts noted. |
| Jerome Seidenfeld,* PhD (TEC co-principal investigator) | Blue Cross and Blue Shield Assoc Technology Evaluation Center Chicago, IL | No conflicts noted. |
| Investigator . | Institution (specialty) . | Conflict of interest disclosure statement . |
|---|---|---|
| Michael S. Gordon, MD (ASCO Co-Chair, TEC panel member) | Univ of Arizona HSC Phoenix, AZ (medical oncology/hematology) | Consultant within the last 2 years for Amgen; received research funding from Amgen; received honoraria directly in excess of $2000 per year or $5000 over a 3-year period from Amgen; a member on the Board of Directors or Advisory Committee of Amgen. |
| Alan E. Lichtin, MD (ASH Co-Chair, TEC panel member) | Cleveland Clinic Foundation Cleveland, OH (medical oncology/hematology) | No conflicts noted. |
| Charles L. Bennett, MD, PhD (TEC panel member) | VA Chicago Health Care System Chicago, IL (medical oncology/hematology) | Consultant within the last 2 years for OrthoBiotech and Amgen; received research funding from OrthoBiotech and Amgen. |
| David Cella, PhD | Evanston Northwestern Healthcare Evanston, IL (quality of life) | Consultant within the last 2 years for Amgen and OrthoBiotech; received research funding from Amgen and OrthoBiotech; received honoraria directly in excess of $2000 per year or $5000 over a 3-year period from Amgen and OrthoBiotech. |
| Benjamin Djulbegovic, MD, PhD | H. Lee Moffitt Cancer Ctr, Univ of South Florida Tampa, FL (medical oncology/hematology) | No conflicts noted. |
| Matthew J. Goode | Mesa, AZ (patient representative) | No conflicts noted. |
| Ann A. Jakubowski, MD, PhD | Memorial Sloan-Kettering Cancer Ctr New York, NY (medical oncology/hematology) | No conflicts noted. |
| Stephanie J. Lee, MD, MPH | Dana Farber Cancer Inst Boston, MA (medical oncology/hematology) | No conflicts noted. |
| Carole B. Miller, MD | St Agnes Hospital Baltimore, MD (medical oncology) | Received research funding from OrthoBiotech and Amgen; received honoraria directly in excess of $2000 per year or $5000 over a 3-year period from Amgen. |
| Mark U. Rarick, MD | NW Kaiser Permanente Portland, OR (hematology) | No conflicts noted. |
| David H. Regan, MD | Northwest Cancer Specialists Portland, OR (hematology) | No conflicts noted. |
| Steven H. Woolf, MD, MPH | Virginia Commonwealth Univ Fairfax, VA (internal medicine/methodological consultant) | No conflicts noted. |
| J. Douglas Rizzo,* MD | Medical College of Wisconsin IBMTR/ABMTR Milwaukee, WI (medical oncology/hematology) | No conflicts noted. |
| George P. Browman,* MD | Hamilton Regional Cancer Ctr Hamilton, Ontario Canada (medical oncology) | No conflicts noted. |
| Jerome Seidenfeld,* PhD (TEC co-principal investigator) | Blue Cross and Blue Shield Assoc Technology Evaluation Center Chicago, IL | No conflicts noted. |